Bioverativ (NASDAQ:BIVV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday. The brokerage currently has a $60.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 9.19% from the stock’s previous close.
According to Zacks, “Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. “
Several other brokerages also recently commented on BIVV. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $71.00 target price on shares of Bioverativ in a report on Monday, October 23rd. Morgan Stanley reaffirmed an “underweight” rating and set a $47.00 target price (up previously from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Royal Bank of Canada assumed coverage on shares of Bioverativ in a report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 target price for the company. Argus raised shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a report on Wednesday, September 20th. Finally, Deutsche Bank set a $53.00 target price on shares of Bioverativ and gave the stock a “hold” rating in a report on Monday, November 20th. One analyst has rated the stock with a sell rating, eight have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $60.33.
Bioverativ (NASDAQ:BIVV) last announced its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.25. Bioverativ had a net margin of 23.29% and a return on equity of 38.29%. The company had revenue of $291.60 million during the quarter, compared to the consensus estimate of $285.45 million. The company’s revenue for the quarter was up 27.2% on a year-over-year basis. equities analysts anticipate that Bioverativ will post 2.45 earnings per share for the current year.
Institutional investors have recently modified their holdings of the business. BP PLC acquired a new stake in Bioverativ in the 3rd quarter worth about $799,000. Whittier Trust Co. of Nevada Inc. acquired a new stake in Bioverativ in the 3rd quarter worth about $293,000. Catalyst Capital Advisors LLC acquired a new stake in Bioverativ in the 3rd quarter worth about $5,707,000. American Century Companies Inc. acquired a new stake in Bioverativ in the 3rd quarter worth about $48,168,000. Finally, BNP Paribas Arbitrage SA acquired a new position in shares of Bioverativ in the 3rd quarter valued at approximately $21,728,000. Institutional investors and hedge funds own 95.99% of the company’s stock.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.